THE EFFECT OF MERATRAN ON TWENTY-FIVE INSTITUTIONALIZED MENTAL PATIENTS
Abstract
A study was conducted on 25 institutionalized psychotic patients with chronic courses, selected because of their depressive and/or regressive symptoms.
Meratran was found to be a central nervous system stimulant useful in the field of psychiatry and with certain indications and contraindications: (1) indications: (a) schizophrenics without delusions having restriction of interest and activity and with depressant features, (b) psycho-motor retardation and/or blocking of communication, (c) long-term hospitalized schizophrenics with severe deterioration; (2) contraindications: (a) patients with delusions, (b) patients with anxiety, (c) disturbed patients with cerebral arteriosclerosis.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
